$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
多吉美(索拉非尼)肾癌靶向药物
2025-10-19 11:44:20
Check Details
乐伐替尼治疗肾癌的临床数据
2025-10-19 11:44:20
Check Details
舒尼替尼用于肾癌患者术后辅助安全有效
2025-10-19 11:44:20
Check Details
仑伐替尼联合PD-1药物治疗肾癌
2025-10-19 11:44:20
Check Details
卡博替尼治疗晚期前列腺癌患者:II期试验结果
2025-10-19 11:44:20
Check Details
依维莫司适应于舒尼替尼耐药的肾癌患者
2025-10-19 11:44:20
Check Details
索拉非尼肾癌靶向药物
2025-10-19 11:44:20
Check Details
舒尼替尼获批肾癌术后辅助治疗用药
2025-10-19 11:44:20
Check Details
卡博替尼治疗肝细胞癌:3期CELESTIAL研究
2025-10-19 11:44:20
Check Details
卡博替尼一线治疗肾癌优于舒尼替尼
2025-10-19 11:44:20
Check Details
依维莫司肾细胞癌靶向治疗用药
2025-10-19 11:44:20
Check Details
舒尼替尼获批肾癌术后辅助治疗
2025-10-19 11:44:20
Check Details
1
2
...
2095
2096
2097
2098
2099
2100
2101
...
4153
4154
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Cabozantinib: Pivotal Advancements and Global Implications in Multi-Cancer Treatment with Multi-Kinase Inhibition
2
Tucatinib (Tukysa): A Precision Medicine for HER2-Positive Breast & Colorectal Cancer
3
Global Breakthrough: Pralsetinib - Precision Medicine for RET Mutation-Driven Cancers
4
Elacestrant: Precision Therapy for ESR1-Mutant Resistant HR+/HER2- Advanced Breast Cancer
5
Selpercatinib Complete Medication Guide: Indications, Dosage and Safety Information for RET Inhibitor
6
Complete Guide to Dosage and Dose Adjustment of Entrectinib
7
Comprehensive Analysis of Bleeding Risk with Tepotinib in MET-Mutated Non-Small Cell Lung Cancer
8
Lomustine vs Temozolomide: Comprehensive Comparison of Efficacy and Safety in Glioma Treatment
9
Tepotinib and Osimertinib: Current Status and Clinical Positioning of Combination Therapy in Non-Small Cell Lung Cancer
10
Tumor Shrinkage Effect and Core Therapeutic Value of Pazopanib
11
Tabrecta (Capmatinib): A Targeted Therapy for METex14-Mutated NSCLC
12
Pazopanib Shows Promise as Second-Line Therapy for Aggressive Skin Cancer